Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Silo Pharma (SILO) EBITDA Margin (2019 - 2025)

Silo Pharma's EBITDA Margin history spans 7 years, with the latest figure at 6150.66% for Q3 2025.

  • For Q3 2025, EBITDA Margin fell 106305.0% year-over-year to 6150.66%; the TTM value through Sep 2025 reached 7052.84%, down 183396.0%, while the annual FY2024 figure was 6080.6%, 93940.0% down from the prior year.
  • EBITDA Margin for Q3 2025 was 6150.66% at Silo Pharma, up from 6687.56% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 574643.9% in Q4 2021 and bottomed at 9697.09% in Q4 2024.
  • The 5-year median for EBITDA Margin is 5178.64% (2024), against an average of 32743.04%.
  • The largest annual shift saw EBITDA Margin surged 57731733bps in 2021 before it plummeted -58386853bps in 2022.
  • A 5-year view of EBITDA Margin shows it stood at 574643.9% in 2021, then plummeted by -102bps to 9224.63% in 2022, then soared by 32bps to 6250.31% in 2023, then plummeted by -55bps to 9697.09% in 2024, then skyrocketed by 37bps to 6150.66% in 2025.
  • Per Business Quant, the three most recent readings for SILO's EBITDA Margin are 6150.66% (Q3 2025), 6687.56% (Q2 2025), and 5675.98% (Q1 2025).